Literature DB >> 29353121

Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.

Rene L Utianski1, Jennifer L Whitwell2, Christopher G Schwarz2, Matthew L Senjem3, Nirubol Tosakulwong4, Joseph R Duffy5, Heather M Clark5, Mary M Machulda6, Ronald C Petersen7, Clifford R Jack2, Val J Lowe8, Keith A Josephs9.   

Abstract

Apraxia of speech is a motor speech disorder characterized by combinations of slow speaking rate, abnormal prosody, distorted sound substitutions, and trial-and-error articulatory movements. Apraxia of speech is due to abnormal planning and/or programming of speech production. It is referred to as primary progressive apraxia of speech (PPAOS) when it is the only symptom of a neurodegenerative condition. Past reports suggest an association of PPAOS with primary 4-repeat (4R) tau (e.g., progressive supranuclear palsy, corticobasal degeneration), rather than amyloid, pathology. The goal of the current study was to investigate the distribution of tau tracer uptake using [18F]AV-1451 positron emission tomography (PET) imaging in patients with PPAOS. Fourteen PPAOS patients underwent [18F]AV-1451 PET (tau-PET) imaging, [C11] Pittsburgh Compound B (PiB) PET and structural MRI and were matched 3:1 by age and sex to 42 cognitively normal controls. Tau-PET uptake was assessed at the region-of-interest (ROI) level and at the voxel-level. The PPAOS group (n = 14) showed increased tau-PET uptake in the precentral gyrus, supplementary motor area and Broca's area compared to controls. To examine whether tau deposition in Broca's area was related to the presence of aphasia, we examined a subgroup of the PPAOS patients who had predominant apraxia of speech, with concomitant aphasia (PPAOSa; n = 7). The PPAOSa patients showed tau-PET uptake in the same regions as the whole group. However, the remaining seven patients who did not have aphasia showed uptake only in superior premotor and precentral cortices, with no uptake observed in Broca's area. This cross-sectional study demonstrates that elevated tau tracer uptake is observed using [18F]AV-1451 in PPAOS. Further, it appears that [18F]AV-1451 is sensitive to the regional distribution of tau deposition in different stages of PPAOS, given the relationship between tau signal in Broca's area and the presence of aphasia.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Frontotemporal dementia; Primary progressive aphasia; Primary progressive apraxia of speech; Tau imaging

Mesh:

Substances:

Year:  2018        PMID: 29353121      PMCID: PMC5800944          DOI: 10.1016/j.cortex.2017.12.021

Source DB:  PubMed          Journal:  Cortex        ISSN: 0010-9452            Impact factor:   4.027


  59 in total

1.  Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy.

Authors:  Gesine Respondek; Sigrun Roeber; Hans Kretzschmar; Claire Troakes; Safa Al-Sarraj; Ellen Gelpi; Carles Gaig; Wang Zheng Chiu; John C van Swieten; Wolfgang H Oertel; Günter U Höglinger
Journal:  Mov Disord       Date:  2013-02-21       Impact factor: 10.338

2.  Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.

Authors:  K A Josephs; B F Boeve; J R Duffy; G E Smith; D S Knopman; J E Parisi; R C Petersen; D W Dickson
Journal:  Neurocase       Date:  2005-08       Impact factor: 0.881

3.  Primary progressive apraxia of speech: clinical features and acoustic and neurologic correlates.

Authors:  Joseph R Duffy; Edythe A Strand; Heather Clark; Mary Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Am J Speech Lang Pathol       Date:  2015-05       Impact factor: 2.408

4.  An empirically derived short form of the Boston naming test.

Authors:  A E Lansing; R J Ivnik; C M Cullum; C Randolph
Journal:  Arch Clin Neuropsychol       Date:  1999-08       Impact factor: 2.813

5.  The Apraxia of Speech Rating Scale: a tool for diagnosis and description of apraxia of speech.

Authors:  Edythe A Strand; Joseph R Duffy; Heather M Clark; Keith Josephs
Journal:  J Commun Disord       Date:  2014-07-14       Impact factor: 2.288

6.  Cognition and anatomy in three variants of primary progressive aphasia.

Authors:  Maria Luisa Gorno-Tempini; Nina F Dronkers; Katherine P Rankin; Jennifer M Ogar; La Phengrasamy; Howard J Rosen; Julene K Johnson; Michael W Weiner; Bruce L Miller
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

7.  18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

Authors:  Daniel R Schonhaut; Corey T McMillan; Salvatore Spina; Bradford C Dickerson; Andrew Siderowf; Michael D Devous; Richard Tsai; Joseph Winer; David S Russell; Irene Litvan; Erik D Roberson; William W Seeley; Lea T Grinberg; Joel H Kramer; Bruce L Miller; Peter Pressman; Ilya Nasrallah; Suzanne L Baker; Stephen N Gomperts; Keith A Johnson; Murray Grossman; William J Jagust; Adam L Boxer; Gil D Rabinovici
Journal:  Ann Neurol       Date:  2017-10       Impact factor: 10.422

8.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

9.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.

Authors:  Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad
Journal:  Alzheimers Dement       Date:  2016-02-15       Impact factor: 21.566

10.  In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Authors:  Ruben Smith; Michael Schöll; Håkan Widner; Danielle van Westen; Per Svenningsson; Douglas Hägerström; Tomas Ohlsson; Jonas Jögi; Christer Nilsson; Oskar Hansson
Journal:  Neurology       Date:  2017-07-28       Impact factor: 9.910

View more
  24 in total

1.  Non-right handed primary progressive apraxia of speech.

Authors:  Hugo Botha; Joseph R Duffy; Jennifer L Whitwell; Edythe A Strand; Mary M Machulda; Anthony J Spychalla; Nirubol Tosakulwong; Matthew L Senjem; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  J Neurol Sci       Date:  2018-05-07       Impact factor: 3.181

2.  [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window.

Authors:  Julien Lagarde; Pauline Olivieri; Fabien Caillé; Philippe Gervais; Jean-Claude Baron; Michel Bottlaender; Marie Sarazin
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

Review 3.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

4.  Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.

Authors:  Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Ann Neurol       Date:  2020-09-12       Impact factor: 10.422

5.  Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech.

Authors:  Rene L Utianski; Peter R Martin; Hugo Botha; Christopher G Schwarz; Joseph R Duffy; Ronald C Petersen; David S Knopman; Heather M Clark; Alissa M Butts; Mary M Machulda; Clifford R Jack; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Cortex       Date:  2019-11-19       Impact factor: 4.027

6.  Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech.

Authors:  R L Utianski; J L Whitwell; C G Schwarz; J R Duffy; H Botha; H M Clark; M M Machulda; M L Senjem; D S Knopman; R C Petersen; C R Jack; V J Lowe; K A Josephs
Journal:  Eur J Neurol       Date:  2018-07-26       Impact factor: 6.089

7.  Electroencephalography in Primary Progressive Aphasia and Apraxia of Speech.

Authors:  Rene L Utianski; John N Caviness; Gregory A Worrell; Joseph R Duffy; Heather M Clark; Mary M Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Aphasiology       Date:  2018-11-16       Impact factor: 2.773

8.  Diagnostic Assessment in Primary Progressive Aphasia: An Illustrative Case Example.

Authors:  Eduardo Europa; Leonardo Iaccarino; David C Perry; Elizabeth Weis; Ariane E Welch; Gil D Rabinovici; Bruce L Miller; Maria Luisa Gorno-Tempini; Maya L Henry
Journal:  Am J Speech Lang Pathol       Date:  2020-09-10       Impact factor: 2.408

9.  Multimodal 18F-AV-1451 and MRI Findings in Nonfluent Variant of Primary Progressive Aphasia: Possible Insights on Nodal Propagation of Tau Protein Across the Syntactic Network.

Authors:  Belen Pascual; Quentin Funk; Paolo Zanotti-Fregonara; Neha Pal; Elijah Rockers; Meixiang Yu; Bryan Spann; Gustavo C Román; Paul E Schulz; Christof Karmonik; Stanley H Appel; Joseph C Masdeu
Journal:  J Nucl Med       Date:  2019-07-26       Impact factor: 10.057

Review 10.  Differential Diagnosis of Apraxia of Speech in Children and Adults: A Scoping Review.

Authors:  Kristen M Allison; Claire Cordella; Jenya Iuzzini-Seigel; Jordan R Green
Journal:  J Speech Lang Hear Res       Date:  2020-08-12       Impact factor: 2.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.